PSTI Pluristem Therapeutics Inc

Between December 13, 2022 and December 19, 2022, Pluri Inc. (the “Company”) executed Securities Purchase Agreements (the “Securities Purchase Agreements”) with accredited and non-U.S. investors relating to a private placement offering (the “Offerings”) of an aggregate of 8,020,900 common shares, $0.00001 par value per share (the “Common Shares”), and warrants (the “Warrants”) to purchase up to 8,020,900 Common Shares. On December 13, 2022, the Company executed securities purchase agreements to sell, at a purchase price of $1.03 per share, up to 5,579,883 Common Shares and Warrants to purchase up to 5,579,883 Common Shares, with an exercise price of $1.03 per share and a term of three years. On December 14, 2022, the Company executed securities purchase agreements to sell, at a purchase price of $1.05 per share, up to 2,068,517 Common Shares and Warrants to purchase up to 2,068,517 Common Shares, with an exercise price of $1.05 per share and a term of three years. On December 15, 2022, the Company executed securities purchase agreements to sell, at a purchase price of $1.06 per share, up to 237,500 Common Shares and Warrants to purchase up to 237,500 Common Shares, with an exercise price of $1.06 per share and a term of three years. On December 19, 2022, the Company executed a securities purchase agreement to sell, at a purchase price of $1.09 per share, up to 135,000 Common Shares and Warrants to purchase up to 135,000 Common Shares, with an exercise price of $1.09 per share and a term of three years. The Warrants sold in the Offerings will be exercisable upon the later of six months from their issuance date, or until the Company increases its authorized shares. The Offerings are expected to close between December 15, 2022 and January 31, 2023.

In addition, the purchasers in the Offering agreed to execute proxies permitting the Company’s Chief Executive Officer and Chief Financial Officer to vote the securities purchased in the Offerings in favor of any shareholder vote relating to a future increase of the Company’s authorized shares. Pursuant to the Securities Purchase Agreement, the Company agreed to hold a meeting of shareholders within 200 days of the execution of the Securities Purchase Agreements for the purpose of increasing the Company’s authorized shares.

The securities issued with respect to the Offerings are exempt from the registration requirements of the Securities Act of 1933, as amended (the “Securities Act”), pursuant to Section 4(a)(2) of the Securities Act and/or Rule 506(b) of Regulation D and Regulation S promulgated thereunder. The securities have not been registered under the Securities Act and may not be sold in the United States absent registration or an exemption from registration. This Current Report on Form 8-K shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. 

The foregoing descriptions of the Warrants and Securities Purchase Agreements are not complete and are qualified in their entirety by reference to the full text of the forms of Warrants and Securities Purchase Agreements, copies of which are filed as Exhibits 4.1 and 10.1, respectively, to this Current Report on Form 8-K and are incorporated herein by reference.